Navigation Links
Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes
Date:10/11/2007

ANN ARBOR, Mich., Oct. 11 /PRNewswire/ -- Compendia Bioscience, Inc. today announced the receipt of a $2.4 million SBIR Fast Track Award from the National Cancer Institute to support the project entitled "Development of Oncomine Professional as a Platform for Biopharmaceutical Research and Development".

(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )

Compendia co-founder Dan Rhodes Ph.D., who will serve as the principal investigator for this project, will assume a full time position at Compendia Bioscience as Chief Executive Officer. Current CEO John Freshley will remain with the company as Chief Business Officer overseeing sales, marketing and corporate development.

"We are thrilled with this award from the NCI and are looking forward to executing the project, which we expect will lead to increased applicability of Oncomine Professional to drug discovery and development," said Dr. Rhodes. "And on a personal level, I am excited to have the opportunity to increase my level of commitment to Compendia."

"Compendia was founded in 2006 to extend Oncomine the commercial sector. Over the past year we have seen ever increasing acceptance of Oncomine in the biopharmaceutical arena, and with that growing sales, marketing, and business development demands," commented John Freshley. "I am looking forward to concentrating on the continued commercial adaptation of this important product."

Oncomine, a dynamic system that combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization, facilitates rapid and reliable biomarker and therapeutic target discovery, validation, and prioritization.

The NIH Fast-Track application process expedites award decisions and funding of SBIR Phase II applications for scientifically meritorious projects that have a high potential for commercialization. The Fast-Track process allows Phase I and II grant applications to be submitted and reviewed together.

About Compendia Bioscience, Inc. Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes."


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Bioscience clusters: Too many or room for more?
5. Quintessence Biosciences names new president
6. Caden Biosciences may signal critical mass
7. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
8. WARF signs licensing pact with BD Biosciences
9. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
10. Bioscience beats beer
11. State awards QRG Biosciences development grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017  BioGenex, a global leader in ... a novel system for quantitative immunohistochemistry (IHC). The ... of Rochester (NY, USA) and Konica-Minolta Inc. ( ... is able to accurately quantify the expression of ... growth factor receptor-2) in clinical samples. Quantitative IHC ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be ... will be held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). ... They provide an opportunity to interact with peers, make new connections and talk bio ...
(Date:2/16/2017)... 16, 2017 Research and Markets ... Global Markets" report to their offering. ... ... biobrick parts, delivery plasmids, chassis organisms, synthetic cells, production ... genome editing, bioinformatics and specialty media) and enabled technologies ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... report to their offering. ... The global voice recognition biometrics market to grow ... The report covers the present scenario and the growth prospects ... the market size, the report considers the revenue generated from the ...
Breaking Biology News(10 mins):